Skip to content
Nanopharm-logo-with-signature-Pantone (1)
  • Home
  • About Us

    About Us

    Leadership Team

    Our Scientists
  • Services

    Product Development

    Preformulation & Preclinical

    Formulation & Drug Product Development

    Clinical Development

    Clinical Trial Manufacturing

    cGMP Release & Stability Testing

    Analytical Services

    Research & Development

    Spray Characterization

    Method Development
    cGMP Release & Stability

    IVBE & CMC Studies

    Alternative Bioequivalence

    In-Silico Modeling

    SmartTrack™

    PBPK Modeling

    Regional Deposition Modeling

    Regulatory

    Consultancy

    Alternative Bioequivalence
  • OINDP Expertise

    Nasal

    Nasal Powders

    Nasal Sprays

    Nasal Cast Deposition

    Inhalation

    DPI

    pMDI

    Low GWP Propellant pMDI

    Nebulizers

    Inhaled Biologics

    Generics & Lifecycle Management

    Reformulation & Repositioning

    IVBE

    Alternative Bioequivalence
  • Resources

    Resources

    Scientific Publications

    White Papers

    Posters
  • News & Events
  • Contact Us
  • Careers

Category: Analytical Services

Accelerating OINDP Development with Nanopharm

Discover how Nanopharm, supports OINDP development from preclinical to CGMP with SmartTrack™, in silico modeling, and regulatory expertise.

Advancing Alternative Bioequivalence for OINDPs

Nanopharm & Fluidda explore FDA’s progress in alternative bioequivalence for OINDPs, Model Master Files (MMF), and future regulatory pathways.

In Silico Bioequivalence Beyond Generic Drug Development

Nanopharm & Fluidda discuss FDA’s in silico bioequivalence methods for alternative pathways beyond generics in inhalation drug development.

FDA’s Evolving Stance on In-Silico Studies in Bioequivalence Testing

Discover how the FDA’s evolving view on in-silico methods, with insights from Nanopharm and FLUIDDA, impacts bioequivalence and generic drugs.

FDA New Inhaled Product Guidelines: Bioequivalence & PSGs

Explore Nanopharm & Fluidda discuss FDA’s revised inhaled product guidelines (PSGs) and alternative bioequivalence pathways for generics.

Novel Aerosol Apparatus for Inhaler Testing in OINDPs

Explore a case study for UniDose in the development of a novel aerosol collection apparatus for dissolution testing of orally inhaled drugs.

Nanopharm Case Study on Computational Modelling

Accelerate injectable drug reformulation for nasal delivery using modelling. Uncover clinical benefits and innovation in nasal pharmaceuticals.

Nanopharm’s SmartTrack: Accelerating OINDP Respiratory Drug Delivery

Revolutionize your OINDP respiratory drug delivery with Nanopharm’s SmartTrack. Accelerate development and mitigate risks through expert formulation and integrated solutions. Your pathway to success starts here.

Nanopharm’s Role in OINDP Bioequivalence & Pharmacokinetics

Explore Nanopharm’s groundbreaking methods in OINDP bioequivalence and pharmacokinetics. Learn how in vitro and in vivo studies are revolutionizing drug development and solubility.

Nanopharm: cGMP Drug Development in OINDP

Nanopharm expands with cGMP facilities for advanced drug development in OINDP. Specializing in biologics characterization and particle engineering.

Next →
  CONTACT
+44 (0) 1633 372200
info@nanopharm.co.uk

Nanopharm Ltd
Franklin House, Grange Road, Cwmbran, NP44 3WY, United Kingdom   

STAY CONNECTED

Linkedin Youtube
General Terms and Conditions of Use and Privacy Policy
Terms & Conditions of Sales

© 2024. Nanopharm Ltd. All rights reserved.